Adult Psychiatry· 14 min read
GLP-1 Medications and Mental Health: What Your Psychiatrist Wants You to Know About Ozempic, Mounjaro, and Beyond
GLP-1 drugs like Ozempic and Mounjaro are known for weight and blood sugar. They also act on the brain, which makes them a psychiatric concern. Millions of patients are now on GLP-1 receptor agonists for diabetes and weight loss. These medications are being prescribed across primary care, endocrinology, obesity medicine, and increasingly through telehealth platforms and specialty clinics. That prescribing is clinically appropriate. The gap is on the psychiatry side: most psychiatrists don’t ask about GLP-1 use, aren’t trained to monitor for the psychiatric effects of these medications, and may not realize that a significant portion of their caseload is now taking drugs that cross the blood-brain barrier and act on reward, mood, and appetite circuitry.
If the question is less about the drug and more about the weight itself, our piece on whether losing weight can improve depression covers what the evidence shows.
For the prescribing side of this, see whether a psychiatrist can prescribe weight loss medication in North Carolina.
How much weight you lose also depends on which drug you take, something I compare in a piece on semaglutide vs tirzepatide vs retatrutide.
That gap matters. GLP-1 agonists act on brain regions involved in reward, mood regulation, impulse control, and appetite signaling. Whether those central effects help or harm psychiatric patients depends on whether anyone is monitoring for them.
For the wider treatment picture, see my guide to depression treatment in North Carolina. If depression hasn’t improved after two or more antidepressants, my treatment-resistant depression page covers what I review next.
These brain effects are one strand of a larger shift in how psychiatry thinks about metabolism, which I unpack in my overview of metabolic psychiatry.
This article covers what the psychiatric research actually shows for GLP-1 agonists (semaglutide, tirzepatide, retatrutide), how they interact with mood, addiction, and eating disorders, why psychiatric oversight matters, and how emerging metabolic compounds (5-Amino-1MQ, MOTS-c, AOD-9604, NMN+) fit into a psychiatrist’s toolkit for patients at the intersection of metabolic and mental health.
What GLP-1 Receptor Agonists Do in the Brain
GLP-1 (glucagon-like peptide-1) is an incretin hormone produced in the gut after eating. It signals the pancreas to release insulin, slows gastric emptying, and reduces appetite. But GLP-1 receptors are not limited to the gut and pancreas. They are expressed throughout the central nervous system, including the hypothalamus, hippocampus, amygdala, ventral tegmental area, and nucleus accumbens.
Those last two regions are the core of the brain’s reward circuitry. The ventral tegmental area produces dopamine. The nucleus accumbens processes reward signals that drive motivation, craving, and pleasure. When GLP-1 agonists bind receptors in these areas, they modulate the same dopaminergic pathways involved in addiction, binge eating, depression, and anhedonia.
This is not a side effect. It is a central mechanism of action. Understanding it is essential for any clinician managing psychiatric patients who are also on GLP-1 therapy.
The Psychiatric Evidence: What the Research Shows
Depression and Anxiety
The data is contradictory, and that contradiction is exactly why psychiatric oversight matters.
A major national cohort study published in The Lancet Psychiatry in March 2026 followed nearly 100,000 Swedish patients with depression or anxiety who also had type 2 diabetes or obesity. Semaglutide was associated with a 42% lower risk of worsening mental illness compared to periods without GLP-1 use. Depression-specific risk dropped 44%. Anxiety risk dropped 38%. Substance use disorder outcomes improved by 47% (Lancet Psychiatry 2026).
On the other side, a pharmacovigilance analysis of over 2 million adverse event reports in VigiBase found statistically significant signals for depression (aROR 1.70), anxiety (aROR 1.26), and suicidal behavior (aROR 1.45) with semaglutide specifically (Clinical Nutrition ESPEN 2025). A separate community-based cohort study found a 195% higher risk of major depression and 108% higher risk of anxiety in GLP-1 RA users compared to matched controls (Scientific Reports 2024).
How can both be true? The answer likely involves patient selection, baseline psychiatric vulnerability, and the difference between population-level observational data and pharmacovigilance signal detection. The Lancet study used within-individual comparisons (the same person on vs. off the medication), which controls for confounders that cross-sectional studies cannot. The pharmacovigilance data captures spontaneous reports, which are biased toward adverse events and cannot establish causation.
The clinical takeaway: GLP-1 agonists likely benefit the majority of patients with comorbid metabolic and psychiatric conditions, but a meaningful subset experiences psychiatric worsening. The patients most likely to benefit metabolically (those with severe obesity and long-standing insulin resistance) may also carry the highest psychiatric risk due to overlapping neuroinflammatory and HPA axis dysregulation.
A psychiatrist involved in the treatment team can stratify that risk. Without psychiatric input, the patients most likely to experience mood changes on GLP-1 therapy are also the least likely to be monitored for them. To learn more about the intersection of hormonal and psychiatric treatment, see our article here. This multifactorial view of depression aligns with research questioning the chemical imbalance model.
Alcohol and Substance Use
GLP-1 medications also show early promise for reducing drinking, working through the same reward circuitry. I cover the trials, the mechanism, and who it fits in a dedicated piece on GLP-1 and alcohol.
Binge Eating Disorder
GLP-1 agonists reduce “food noise,” the constant preoccupation with eating that patients with binge eating disorder describe. This effect goes beyond appetite suppression. Patients report a reduction in the compulsive quality of eating, a decreased drive to eat in response to emotional triggers, and improved self-regulation around food. The pharmacovigilance data actually shows higher reporting of eating disorder events with GLP-1 agonists (aROR 4.17 to 6.80), but this likely reflects increased detection and reporting in a population already at elevated risk for eating pathology, not a causal worsening of eating disorders.
For patients with binge eating disorder who also have obesity, the clinical picture is nuanced. The medication can reduce binge frequency and improve metabolic health. But the rapid appetite change can also destabilize patients with restrictive eating histories or body dysmorphia. Psychiatric monitoring is essential to distinguish therapeutic appetite reduction from pathological restriction.
Cognitive Effects and Neuroprotection
An eClinicalMedicine propensity-matched cohort study found that semaglutide was not associated with higher risk of any neuropsychiatric outcome compared to other antidiabetic medications over 12 months. The study noted a potential beneficial signal for cognitive deficit and nicotine misuse, warranting validation in clinical trials (eClinicalMedicine 2024). Thirteen ongoing trials registered on ClinicalTrials.gov are evaluating semaglutide for cognitive disorders, substance misuse, psychosis, and depression.
For patients with metabolic syndrome and cognitive complaints (brain fog, concentration difficulty, executive dysfunction), the combination of metabolic improvement and potential central neuroprotective effects makes GLP-1 therapy worth discussing as part of a comprehensive plan that includes psychiatric care.
Semaglutide, Tirzepatide, and Retatrutide: How They Differ
Semaglutide (Ozempic, Wegovy, Rybelsus)
The most studied GLP-1 agonist for psychiatric outcomes. Selective GLP-1 receptor agonist. Weekly subcutaneous injection or daily oral formulation. The Swedish Lancet study showed the strongest psychiatric benefit signal among all GLP-1 agonists studied. Also carries the most pharmacovigilance reports for psychiatric adverse events, likely reflecting higher prescribing volume and longer market exposure rather than higher inherent risk.
Tirzepatide (Mounjaro, Zepbound)
Dual GLP-1/GIP receptor agonist. Produces greater weight loss than semaglutide (up to 20% body weight reduction vs. 15%). Two published case reports demonstrate potential mental health benefits, including dose-dependent mood improvement that preceded significant weight loss, suggesting a direct central effect independent of metabolic improvement (Primary Care Companion CNS Disorders 2025). Psychiatric adverse event reporting in FAERS is lower than semaglutide (2.71% vs. 5.82% of total AEs), though tirzepatide has been on the market for a shorter period.
Retatrutide
Triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 trials are underway. Early data shows up to 24% body weight reduction at 48 weeks. No published psychiatric outcome data yet, but the addition of glucagon receptor agonism introduces a new variable. Glucagon affects hepatic glucose production, energy expenditure, and amino acid metabolism. The psychiatric implications of triple agonism are unstudied and represent a monitoring gap that will widen as prescribing accelerates.
For patients already on psychiatric medications, the drug interaction profile of these agents matters. GLP-1 agonists slow gastric emptying, which can affect the absorption kinetics of oral psychiatric medications (SSRIs, mood stabilizers, stimulants, benzodiazepines). A psychiatrist coordinating care can adjust timing and monitor serum levels when clinically indicated.
Beyond GLP-1: Metabolic Compounds with Psychiatric Relevance
GLP-1 agonists are the headline story, but they are not the only metabolic interventions that intersect with psychiatry. Several emerging compounds target metabolic pathways that directly or indirectly affect brain function.
5-Amino-1MQ
A small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism and fat storage. NNMT is overexpressed in adipose tissue in obesity. By inhibiting NNMT, 5-Amino-1MQ may increase NAD+ levels and activate SIRT1, a longevity-associated enzyme involved in mitochondrial function and cellular stress response. NAD+ depletion is increasingly linked to neurodegenerative processes, cognitive decline, and depression. In preclinical models, NNMT inhibition improved metabolic parameters and body composition. Human clinical data is limited. This compound is available through compounding pharmacies and is relevant for patients interested in metabolic optimization alongside psychiatric treatment.
MOTS-c
A mitochondrial-derived peptide encoded in the mitochondrial genome. MOTS-c regulates metabolic homeostasis by activating AMPK, a master energy sensor. In animal models, MOTS-c improves insulin sensitivity, reduces fat accumulation, and enhances exercise capacity. The psychiatric relevance is indirect but significant: mitochondrial dysfunction is a proposed mechanism in treatment-resistant depression, bipolar disorder, and chronic fatigue. If mitochondrial function improves, downstream effects on energy production, oxidative stress, and neuroinflammation may translate to mood and cognitive benefits. Clinical evidence in humans is early-stage.
AOD-9604
A modified fragment of human growth hormone (amino acids 177-191) studied for its effects on fat metabolism without the growth-promoting or diabetogenic effects of full-length growth hormone. AOD-9604 stimulates lipolysis and inhibits lipogenesis in animal models. It does not appear to affect IGF-1 levels or glucose tolerance. For patients with obesity-related psychiatric symptoms (depression, fatigue, cognitive slowing) who are not candidates for or have failed GLP-1 therapy, AOD-9604 represents an alternative metabolic approach that avoids the GI side effects and reward-pathway modulation of GLP-1 agonists. Peptide availability depends on current compounding regulations. More on peptide access is available on the peptide therapy service page.
NMN+ (Nicotinamide Mononucleotide)
A precursor to NAD+, which is essential for mitochondrial energy production, DNA repair, and sirtuin activation. NAD+ levels decline with age and are lower in patients with obesity, diabetes, and neurodegenerative conditions. Supplementation with NMN has shown improvements in insulin sensitivity, physical endurance, and vascular function in early human trials. The psychiatric angle: NAD+ is required for tryptophan metabolism through the kynurenine pathway. When NAD+ is depleted, tryptophan is shunted away from serotonin production toward neurotoxic metabolites (quinolinic acid), which contributes to neuroinflammation and depression. Restoring NAD+ through NMN supplementation may theoretically redirect tryptophan metabolism back toward serotonin. This is an active area of research with no definitive clinical psychiatric data yet.
For a deeper look at how peptides like BPC-157 and Semax and Selank interact with the same neurobiological systems discussed here, those articles provide the clinical context from a psychiatrist’s perspective. Patients weighing peptides against conventional psychiatric medications can also read Dr. Baghel’s comparison of peptides and SSRIs.
Why a Psychiatrist Should Be Involved When Patients Are on GLP-1 Therapy
GLP-1 agonists are prescribed across multiple specialties for metabolic indications, and appropriately so. The monitoring gap isn’t about who’s prescribing. It’s about the fact that psychiatry as a field hasn’t integrated these medications into its standard intake and monitoring workflows. Most psychiatric evaluations don’t ask whether a patient is on semaglutide or tirzepatide. They should.
When a psychiatrist is aware of GLP-1 use, they can monitor for emergent depression, anxiety, or suicidal ideation. They can evaluate whether mood changes are medication-related or coincidental. They can adjust psychiatric medications if absorption is altered by delayed gastric emptying. They can assess whether the patient’s relationship with food is shifting in a healthy direction or toward restriction. And they can coordinate care with the prescribing physician to ensure metabolic and psychiatric treatment goals are aligned.
For patients who are already in psychiatric treatment and starting a GLP-1 agonist, adding a conversation with their psychiatrist about monitoring expectations is a simple step that can prevent complications. For patients who are on GLP-1 therapy and experiencing mood changes, cognitive shifts, or behavioral changes they did not expect, a psychiatric evaluation can determine whether the medication is contributing and what adjustments are appropriate.
At Baghel Psychiatry, GLP-1 therapy is available as part of the medical weight loss program. Because the same physician manages both psychiatric medications and metabolic interventions, there is no gap between the prescriber and the monitor. One doctor. One plan. No blind spots.
Frequently Asked Questions
Can GLP-1 medications cause depression?
The evidence is mixed. Large cohort studies show a net reduction in depression risk for most patients on semaglutide and liraglutide. However, pharmacovigilance data and case reports document psychiatric worsening in a subset of patients, particularly those with pre-existing psychiatric vulnerability. The clinical recommendation is to monitor mood closely after starting GLP-1 therapy, especially in patients with a history of depression, anxiety, or suicidal ideation. Any new or worsening psychiatric symptoms should prompt evaluation.
Should I tell my psychiatrist if I start Ozempic or Mounjaro?
Yes. GLP-1 agonists affect brain reward pathways, can alter the absorption of oral psychiatric medications through delayed gastric emptying, and carry psychiatric monitoring recommendations. Informing a psychiatrist allows them to adjust timing of medications if needed and monitor for mood changes.
Can GLP-1 medications help with alcohol or drug cravings?
Emerging evidence suggests yes. The first randomized controlled trial of semaglutide for alcohol use disorder (2025) showed reductions in heavy drinking days, cravings, and overall alcohol intake. Animal models show similar effects for cocaine and nicotine. These medications are not FDA-approved for addiction treatment, but the research is advancing rapidly and clinical trials are underway.
What is retatrutide and is it available?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. It is currently in Phase 3 clinical trials and is not yet FDA-approved or commercially available. Early data shows greater weight loss than semaglutide or tirzepatide. No psychiatric outcome data has been published. Compounded versions may be available through some pharmacies, but patients should exercise caution and work with a physician who can monitor both metabolic and psychiatric effects.
What is 5-Amino-1MQ?
5-Amino-1MQ is a small molecule that inhibits NNMT, an enzyme involved in fat storage and energy metabolism. It may increase NAD+ levels and activate longevity-associated pathways. It is available through compounding pharmacies. Human clinical data is limited. It is relevant for patients interested in metabolic optimization as part of a comprehensive treatment plan.
How does Dr. Baghel approach GLP-1 therapy differently than a weight loss clinic?
Weight loss clinics typically prescribe GLP-1 medications without evaluating psychiatric history, current medications, or mood. Dr. Baghel is a board-certified psychiatrist who manages both psychiatric and metabolic treatment under one plan. That means monitoring for mood changes, adjusting psychiatric medications if absorption is affected, screening for eating disorder risk, and coordinating metabolic and mental health goals together.
On a GLP-1 Medication? Your Psychiatrist Should Know.
Dr. Baghel manages psychiatric medications and GLP-1 therapy under one plan. Schedule a free consultation to discuss how your metabolic and mental health treatment can work together.
Baghel Psychiatry, PLLC | Shantanu Baghel, DO | (910) 612-6015 | sbaghel@thebh.us
This article is for educational purposes only and does not constitute medical advice. GLP-1 receptor agonists are FDA-approved for type 2 diabetes and/or chronic weight management. Use for psychiatric conditions is not FDA-approved. Patients should not start, stop, or change medications without consulting their physician. If you are experiencing a mental health crisis, contact 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room.
References
1. Molero Y, et al. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. Lancet Psychiatry. 2026;13(4):327. DOI: 10.1016/S2215-0366(26)00014-3.
2. Nishida K, Chrétien B, et al. Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: a VigiBase study. Clinical Nutrition ESPEN. 2025.
3. Kornelius E, et al. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Scientific Reports. 2024;14:24433.
4. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4). PMID: 39937469.
5. De Giorgi R, et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. eClinicalMedicine. 2024.
6. De Giorgi R, et al. An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders. Nature Mental Health. 2025.
7. Pierret ACS, et al. Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis. JAMA Psychiatry. 2025;82:643-653.
8. Lähteenvuo M, et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025;82:94-98.
9. Wang W, Volkow ND, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024;30:168-176.
10. Kokalj Palandacic A, et al. Association of semaglutide use with depressive symptoms and suicidal behavior: a case report. PMC. 2025.
11. Bhatia GK, et al. Semaglutide: an opportunity or an obstacle? Poster, APA Annual Meeting. 2024.
12. Mental health effects of tirzepatide: a report of 2 patients. Primary Care Companion CNS Disorders. 2025.
13. Frontiers in Endocrinology. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. 2024.